Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis

Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) serve as crucial therapeutic agents in solid tumor treatment. Preclinical investigations suggest a potential protective function of PARPi against endocrine and metabolic impairments. Nevertheless, the existing body of evidence remai...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Shunlian Fu, Pingjin Zou, Zengyi Fang, Xinxiang Zhou, Junyang Chen, Cuicui Gong, Li Quan, Bing Lin, Qiu Chen, Jinyi Lang, Meihua Chen
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2025-01-01
סדרה:	BMC Cancer
נושאים:	PARP inhibitors Endocrine and metabolic abnormalities Meta-analysis
גישה מקוונת:	https://doi.org/10.1186/s12885-025-13579-1
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!